In particular, they reported that, in IQGAP1-silenced breast cancer cells, trastuzumab increased its capacity to decrease HER2 expression and HER2-stimulated activation of the PI3K/AKT cascade [37]. This evidence concerns the gene AKT1 and breast carcinoma.